MNTL
ETF
MNTL
·
UNKNOWN
·
44 holdings
Quick Summary
Price History
Concentration Risk
53.10%
Top-heavy
Low risk
High risk
The top 10 holdings make up 53.10% of this ETF. A bad day for those few names drags the whole fund down with them.
Top Holdings Today
Weighted by position size
VRTX
▼ -1.37%
REGN
▼ -1.05%
ALNY
▼ -3.98%
ARGX
▼ -1.49%
TEVA
▼ -1.11%
NBIX
▼ -2.31%
LLY
▼ -0.11%
CRNX
▼ -1.89%
BIIB
▼ -2.50%
SYK
▼ -0.84%
Weighted avg. of top holdings
▼ -1.69%
Sector Allocation
Healthcare
88.26%
Financial Services
2.23%
Manufacturing
2.14%
Services
0.91%
Top 10 Holdings
53.10% of fund
VRTX
Vertex Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
ALNY
Alnylam Pharmaceuticals Inc
ARGX
Argenx SE
TEVA
Teva Pharmaceutical Industries
NBIX
Neurocrine Biosciences Inc
LLY
Eli Lilly & Co
CRNX
Crinetics Pharmaceuticals Inc
BIIB
Biogen Inc
SYK
Stryker Corp
Other positions
All Holdings (44)
| # | Ticker | Name | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | VRTX | Vertex Pharmaceuticals Inc | 10.46% | 2,298 | 1.02 M |
| 2 | REGN | Regeneron Pharmaceuticals Inc | 6.48% | 1,284 | 629,519.52 |
| 3 | ALNY | Alnylam Pharmaceuticals Inc | 6.22% | 1,982 | 603,637.92 |
| 4 | ARGX | Argenx SE | 5.25% | 890 | 510,201.4 |
| 5 | TEVA | Teva Pharmaceutical Industries | 4.99% | 28,861 | 484,287.58 |
| 6 | NBIX | Neurocrine Biosciences Inc | 4.95% | 3,904 | 480,270.08 |
| 7 | LLY | Eli Lilly & Co | 4.16% | 547 | 403,505.49 |
| 8 | CRNX | Crinetics Pharmaceuticals Inc | 4.11% | 13,066 | 398,643.66 |
| 9 | BIIB | Biogen Inc | 3.34% | 2,501 | 324,604.79 |
| 10 | SYK | Stryker Corp | 3.14% | 798 | 305,346.72 |
Showing top 10 of 44 holdings
·
Listed: 97.58%
·
2.42% in other positions
Related ETFs
Precio Objetivo de Analistas
No hay cobertura de analistas disponible
Growth
Rev 5Y: N/A · Earnings 1Y: N/A
Growth
Rev 5Y: N/A · Earnings 1Y: N/A| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
Profitability
ROE: N/A · Net Margin: N/A
Profitability
ROE: N/A · Net Margin: N/A| Revenue (TTM) | N/A | Net Income (TTM) | N/A |
| ROE | N/A | ROA | N/A |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | N/A |
| ROIC | N/A | FCF Growth (3Y) | N/A |
Safety
D/E: N/A · Current: N/A
Safety
D/E: N/A · Current: N/A| Debt / Equity | N/A | Current Ratio | N/A |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | N/A | Tangible Book Value | N/A |
Dividends
Yield: N/A · Payout: N/A
Dividends
Yield: N/A · Payout: N/A| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
Valuation
P/E: N/A · EV/EBITDA: N/A
Valuation
P/E: N/A · EV/EBITDA: N/A| P/E Ratio | N/A | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | N/A | ||
| Market Cap | N/A | Enterprise Value | N/A |
Per Share
EPS: N/A · FCF/Share: N/A
Per Share
EPS: N/A · FCF/Share: N/A| EPS (Diluted TTM) | N/A | Revenue / Share | N/A |
| FCF / Share | N/A | OCF / Share | N/A |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
Efficiency
FCF Conv: N/A · CapEx/Rev: N/A
Efficiency
FCF Conv: N/A · CapEx/Rev: N/A| CapEx / Revenue | N/A | FCF Conversion | N/A |
| SBC-Adj. FCF | N/A | Growth Momentum | N/A |
Comparación con Pares
vs mediana del sector ETF (25157 pares)
Comparado con empresas similares en ETF
Comparación con Pares
vs mediana del sector ETF (25157 pares) Comparado con empresas similares en ETF| Métrica | Acción | Mediana del Sector |
|---|---|---|
| P/E | — | — |
| P/B | — | — |
| ROE % | — | — |
| Net Margin % | — | — |
| Rev Growth 5Y % | — | — |
| D/E | — | — |
{"event":"ticker_viewed","properties":{"ticker":"MNTL","listing_kind":"etf","pathname":"/etfs/mntl","exchange":"UNKNOWN","country":"US"}}


